{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["ORIGIN Trial Investigators"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["2915-22"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3781572"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(10)"],"pubmed_abstract":["Objective
To assess the success and baseline predictors of maintaining glycemic control for up to 5 years of therapy using basal insulin glargine or standard glycemic care in people with dysglycemia treated with zero or one oral glucose-lowering agents.Research design and methods
Data from 12,537 participants in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were examined by baseline glycemic status (with or without type 2 diabetes) and by therapeutic approach (titrated insulin glargine or standard therapy) using an intention-to-treat analysis. Median values for fasting plasma glucose (FPG) and A1C and percentages with A1C<6.5% (48 mmol/mol) during randomized treatment were calculated. Factors independently associated with maintaining updated mean A"],"journal":["Diabetes care"],"pubmed_title":["Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial."],"pmcid":["PMC3781572"],"funding_grant_id":["RP-PG-0606-1272","RP-DG-1210-10183"],"pubmed_authors":["Probstfield JL","Spinas GA","Ramachandran A","Gerstein HC","Hanefeld M","Johnston P","Rosenstock J","Ryden LE","Dyal L","Riddle MC","ORIGIN Trial Investigators"],"additional_accession":[]},"is_claimable":false,"name":"Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.","description":"Objective
To assess the success and baseline predictors of maintaining glycemic control for up to 5 years of therapy using basal insulin glargine or standard glycemic care in people with dysglycemia treated with zero or one oral glucose-lowering agents.Research design and methods
Data from 12,537 participants in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were examined by baseline glycemic status (with or without type 2 diabetes) and by therapeutic approach (titrated insulin glargine or standard therapy) using an intention-to-treat analysis. Median values for fasting plasma glucose (FPG) and A1C and percentages with A1C<6.5% (48 mmol/mol) during randomized treatment were calculated. Factors independently associated with maintaining updated mean A","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Oct","modification":"2025-04-04T20:52:45.3Z","creation":"2019-03-27T00:13:32Z"},"accession":"S-EPMC3781572","cross_references":{"pubmed":["23656980"],"doi":["10.2337/dc12-2238"]}}